370 related articles for article (PubMed ID: 26222274)
21. Radium 223 dichloride: a multidisciplinary approach to metastatic castration-resistant prostate cancer.
Borsò E; Boni G; Galli L; Ricci S; Farnesi A; Mazzarri S; Cianci C; Mariani G; Falcone A
Future Oncol; 2015; 11(2):323-31. PubMed ID: 25075962
[TBL] [Abstract][Full Text] [Related]
22. Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody.
Vallabhajosula S; Nikolopoulou A; Jhanwar YS; Kaur G; Tagawa ST; Nanus DM; Bander NH; Goldsmith SJ
Curr Radiopharm; 2016; 9(1):44-53. PubMed ID: 25771365
[TBL] [Abstract][Full Text] [Related]
23. Radium 223 for the treatment of metastatic castration-resistant prostate cancer.
Miranda J; Viñal D; Pinto Á
Arch Esp Urol; 2019 Jun; 72(5):500-507. PubMed ID: 31223127
[TBL] [Abstract][Full Text] [Related]
24. Final Outcome of 223Ra-therapy and the Role of 18F-fluoride-PET in Response Evaluation in Metastatic Castration-resistant Prostate Cancer-A Single Institution Experience.
Kairemo K; Milton DR; Etchebehere E; Rohren EM; Macapinlac HA
Curr Radiopharm; 2018; 11(2):147-152. PubMed ID: 29956640
[TBL] [Abstract][Full Text] [Related]
25. Radium-223 dichloride for the treatment of metastatic prostate cancer.
Turner PG; O'Sullivan J
Expert Opin Pharmacother; 2014 Oct; 15(14):2105-11. PubMed ID: 25186336
[TBL] [Abstract][Full Text] [Related]
26. Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis.
Abou DS; Ulmert D; Doucet M; Hobbs RF; Riddle RC; Thorek DL
J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26683407
[TBL] [Abstract][Full Text] [Related]
27. Bone-targeted therapy in castration-resistant prostate cancer: where do we stand?
Gómez Rivas J; Carrion DM; Alvarez-Maestro M; Cathelineau X; Sanchez-Salas R; Di Lorenzo G; Di Maio M; Paul A; Martinez-Piñeiro L; Sartor O; Saad F; Debruyne F
Minerva Urol Nefrol; 2019 Oct; 71(5):445-456. PubMed ID: 31353876
[TBL] [Abstract][Full Text] [Related]
28. GRPR versus PSMA: expression profiles during prostate cancer progression demonstrate the added value of GRPR-targeting theranostic approaches.
Verhoeven M; Ruigrok EAM; van Leenders GJLH; van den Brink L; Balcioglu HE; van Weerden WM; Dalm SU
Front Oncol; 2023; 13():1199432. PubMed ID: 37719014
[TBL] [Abstract][Full Text] [Related]
29. Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid.
Saad F; Segal S; Eastham J
Eur Urol; 2014 Jan; 65(1):146-53. PubMed ID: 22633317
[TBL] [Abstract][Full Text] [Related]
30. Molecular alterations and emerging targets in castration resistant prostate cancer.
Lorente D; De Bono JS
Eur J Cancer; 2014 Mar; 50(4):753-64. PubMed ID: 24418724
[TBL] [Abstract][Full Text] [Related]
31. New developments in the imaging of metastatic prostate cancer.
Beauregard JM; Pouliot F
Curr Opin Support Palliat Care; 2014 Sep; 8(3):265-70. PubMed ID: 25004180
[TBL] [Abstract][Full Text] [Related]
32. Bone-Targeting Radiopharmaceuticals as Monotherapy or Combined With Chemotherapy in Patients With Castration-Resistant Prostate Cancer Metastatic to Bone.
Bouman-Wammes EW; de Klerk JMH; Bloemendal HJ; Van Dodewaard-de Jong JM; Lange R; Ter Heine R; Verheul HMW; Van den Eertwegh AJM
Clin Genitourin Cancer; 2019 Apr; 17(2):e281-e292. PubMed ID: 30555024
[TBL] [Abstract][Full Text] [Related]
33. Hematologic Toxicity From Radium-223 Therapy for Bone Metastases in Castration-Resistant Prostate Cancer: Risk Factors and Practical Considerations.
Jacene H; Gomella L; Yu EY; Rohren EM
Clin Genitourin Cancer; 2018 Aug; 16(4):e919-e926. PubMed ID: 29678471
[TBL] [Abstract][Full Text] [Related]
34. Radionuclide therapy for osseous metastases in prostate cancer.
Abi-Ghanem AS; McGrath MA; Jacene HA
Semin Nucl Med; 2015 Jan; 45(1):66-80. PubMed ID: 25475380
[TBL] [Abstract][Full Text] [Related]
35. Castration-resistant prostate cancer: from new pathophysiology to new treatment.
Sridhar SS; Freedland SJ; Gleave ME; Higano C; Mulders P; Parker C; Sartor O; Saad F
Eur Urol; 2014 Feb; 65(2):289-99. PubMed ID: 23957948
[TBL] [Abstract][Full Text] [Related]
36. Leading causes of castration-resistant prostate cancer.
Lu M; Lu H; Kong Q
Expert Rev Anticancer Ther; 2015 Apr; 15(4):425-32. PubMed ID: 25645203
[TBL] [Abstract][Full Text] [Related]
37. Differences in time to disease progression do not predict for cancer-specific survival in patients receiving immediate or deferred androgen-deprivation therapy for prostate cancer: final results of EORTC randomized trial 30891 with 12 years of follow-up.
Studer UE; Whelan P; Wimpissinger F; Casselman J; de Reijke TM; Knönagel H; Loidl W; Isorna S; Sundaram SK; Collette L;
Eur Urol; 2014 Nov; 66(5):829-38. PubMed ID: 23932338
[TBL] [Abstract][Full Text] [Related]
38. Isotope Therapy for Castrate-Resistant Prostate Cancer: Unique Sequencing and Combinations.
Sartor O
Cancer J; 2016; 22(5):342-346. PubMed ID: 27749328
[TBL] [Abstract][Full Text] [Related]
39. [EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer].
Mottet N; Bellmunt J; Bolla M; Joniau S; Mason M; Matveev V; Schmid HP; van der Kwast T; Wiegel T; Zattoni F; Heidenreich A
Actas Urol Esp; 2011; 35(10):565-79. PubMed ID: 21757258
[TBL] [Abstract][Full Text] [Related]
40. Androgen-regulated gastrin-releasing peptide receptor expression in androgen-dependent human prostate tumor xenografts.
Schroeder RP; de Visser M; van Weerden WM; de Ridder CM; Reneman S; Melis M; Breeman WA; Krenning EP; de Jong M
Int J Cancer; 2010 Jun; 126(12):2826-34. PubMed ID: 19876914
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
